Plaque Psoriasis Archives - Dermatology Advisor

Celastrol-Containing Emollient Balm Improves Signs of Psoriasis and Associated Pruritus

By

Brandon May

September 10, 2020

The tolerance and efficacy of a new celastrol-containing emollient balm for the treatment of plaque psoriasis was evaluated.

Psoriasis

Tapinarof Cream Looks Promising for Plaque Psoriasis

By

Brian Park, PharmD

August 31, 2020

The double-blind, vehicle-controlled studies (PSOARING 1 and PSOARING 2) assessed the efficacy and safety of tapinarof in 1025 patients aged 18 to 75 years with plaque psoriasis.

Psoriasis

Shortened Secukinumab Dosing Interval May Improve Skin Clearance in Suboptimal Responders

By

Brandon May

August 12, 2020

PASI score and skin clearance in suboptimal responders improved when secukinumab dosing was shortened from every 4 weeks to every 2 weeks.

Psoriasis

Stelara Approved for Pediatric Plaque Psoriasis

By

Diana Ernst, RPh

August 5, 2020

The approval of ustekinumab in pediatric patients was based on data from a phase 3 open-label, single-arm study (CADMUS Junior).

Psoriasis

ECLIPSE Trial: Guselkumab Found More Effective for Management of Plaque Psoriasis

By

Brandon May

August 4, 2020

The ECLIPSE study provides important new information to guide longer-term therapy choices among the newer biologic treatment options for psoriasis.

Psoriasis

Bimekizumab Bests Secukinumab in Plaque Psoriasis Trial

By

Brian Park, PharmD

July 31, 2020

Positive results were announced from a phase 3b study comparing bimekizumab (UCB) to secukinumab for the treatment of moderate to severe plaque psoriasis.

Psoriasis

Wynzora Cream Approved for Plaque Psoriasis

By

Brian Park, PharmD

July 29, 2020

Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid, which utilizes the Company’s proprietary PAD Technology platform enabling stability of both agents in an aqueous formulation.

Psoriasis

Mirikizumab Tops Secukinumab in Plaque Psoriasis Trial

By

Brian Park, PharmD

July 23, 2020

Among patients with moderate to severe plaque psoriasis, treatment with mirikizumab (Lilly) was found to be noninferior to secukinumab (Cosentyx; Novartis).